TRT FAQs: Low Testosterone, Fertility, Side Effects & Safety

Male hypogonadism is diagnosed when a man has symptoms and signs consistent with testosterone deficiency together with unequivocally and consistently low testosterone concentrations measured with appropriate testing. Symptoms alone or a single laboratory value is not enough.

No. Endocrine Society guidance recommends confirming the diagnosis by repeating a morning fasting total testosterone measurement. Additional testing may be needed depending on the result and the clinical context.

Testosterone concentrations vary over the day, and morning testing improves consistency when evaluating suspected deficiency. The clinician also considers sleep schedule, illness, medications, and other factors that may affect the result.

No. Fatigue, low libido, mood changes, reduced strength, sleep problems, and concentration difficulties are nonspecific and can have many causes. The diagnosis requires compatible symptoms plus consistently low testosterone levels.

Low testosterone can result from testicular disease, pituitary or hypothalamic problems, medications, systemic illness, obesity, sleep disorders, and other factors. Identifying the cause can change treatment, reveal a reversible contributor, or identify a condition that needs separate evaluation.

TRT may be considered for men with symptoms of testosterone deficiency and consistently low testosterone concentrations after appropriate evaluation. The decision also considers the cause, contraindications, fertility plans, comorbidities, and monitoring requirements.

Yes. Exogenous testosterone can suppress sperm production and may significantly reduce fertility. Endocrine Society guidance recommends against starting testosterone therapy in men who are planning fertility in the near term. Fertility goals should be discussed before treatment.

Testosterone is available in several FDA-approved formulations, including injections and transdermal products. The appropriate formulation depends on patient preference, pharmacology, cost, safety considerations, adherence, and monitoring needs.

Mindfuse Health does not use TRT simply to pursue higher testosterone numbers, anti-aging goals, or performance enhancement. The focus is an accurate diagnosis of hypogonadism and treatment when the potential benefits outweigh the risks.

Endocrine Society guidance recommends against testosterone therapy in several situations, including men planning fertility in the near term and certain conditions such as prostate or breast cancer, elevated hematocrit, untreated severe obstructive sleep apnea, uncontrolled heart failure, recent myocardial infarction or stroke, or thrombophilia. The exact contraindications and precautions require clinician review.

Monitoring is individualized and may include symptom response, testosterone concentrations, hematocrit, adverse effects, cardiovascular and sleep-related issues, and prostate-related assessment when appropriate. Monitoring is part of treatment rather than an optional extra.

They can be relevant contributors. Obesity, sleep disruption, obstructive sleep apnea, medications, systemic illness, and other factors can affect symptoms or testosterone levels. A diagnosis-first approach looks for reversible or treatable contributors rather than assuming TRT is the only answer.

No. In a July 2026 statement, the Endocrine Society emphasized that age alone does not establish hypogonadism and that the diagnosis requires symptoms plus consistently low, accurately measured testosterone. Population-wide screening of asymptomatic men is not recommended.

Telehealth prescribing of controlled medications must comply with federal and state law. Federal telemedicine flexibilities for Schedule II–V controlled medications are currently extended through December 31, 2026, but eligibility and prescribing requirements still apply. A telehealth visit does not guarantee TRT or any controlled prescription.